Isaac Israel

Chief Executive Officer

Gil Efron 

Deputy CEO and Chief Financial Officer

Gil Efron was appointed Kitov’s Chief Financial Officer in 2018. Mr. Efron brings to Kitov over 25 years of experience in financial management positions. Most recently, he served as Deputy CEO and CFO of Kamada, a NASDAQ and TASE dual-listed plasma-derived protein therapeutics company. Previously, he was CFO of RRsat Global Communications Network, where he led its listing on NASDAQ. Before that, Mr. Efron served in various finance-related executive positions. Mr. Efron holds a BA in Economics and Accounting and an MBA from the Hebrew University of Jerusalem, and received a certified public accountant’s license in Israel.

Dr. Gil Ben-Menachem – MSc, MBA, PhD

Vice President - Business Development

Hadas Reuveni - PhD

Founder & Chief Technology Officer, TyrNovo

Dr. Hadas Reuveni is a co-inventor of TyrNovo’s technology. She has been engaged with the scientific projects in TyrNovo’s portfolio since 2005, and has nearly two decades of research and development experience in biotechnology. Dr. Reuveni founded and served as CEO of NovoTyr, a biotech start-up company preceding TyrNovo that developed small molecules for the treatment of cancer and neurodegenerative diseases. She also founded and served as a Director and Chief Science Officer of AngioB, a startup that developed GPCR-based agents for multiple indications (2006-2010). Prior to that, she was the Director of Research & Development at Keryx Biopharmaceuticals (NASDAQ: KRX) in 2001-2004. Dr. Reuveni also has served as a scientific consultant for Integra Holdings, Campus Bio Management, and BioLineRX (NASDAQ/TASE: BLRX). Dr. Reuveni received her PhD from The Hebrew University of Jerusalem.